ARVN
- Arvinas, Inc.
()
Overview
Company Summary
Arvinas, Inc. is a biopharmaceutical company that specializes in using protein degradation to develop innovative therapies for various diseases. The company's proprietary platform, known as PROTAC� (PROteolysis TArgeting Chimeras), harnesses the body's natural protein disposal system to selectively remove disease-causing proteins.
ARVN's approach involves designing small molecules called PROTACs that target specific disease-associated proteins. These PROTACs consist of two parts: a binding molecule that recognizes the target protein and a recruiting molecule that brings in an enzyme responsible for protein degradation. When the PROTAC binds to its target protein, it activates the protein degradation machinery, leading to the destruction of the disease-causing protein.
The company focuses on developing therapies for diseases with limited treatment options, including cancer, neurodegenerative disorders, and autoimmune conditions. Through its research and development efforts, ARVN aims to advance the field of protein degradation and unlock new therapeutic possibilities.
In addition to its innovative platform, Arvinas collaborates with academic institutions, pharmaceutical companies, and other research organizations to accelerate the discovery and development of novel therapies. By leveraging their expertise in protein degradation, the company strives to bring life-changing treatments to patients in need.
As a biopharmaceutical company, Arvinas, Inc. operates in a highly regulated industry, conducting preclinical and clinical trials to evaluate the safety and efficacy of their therapeutic candidates. Their ultimate goal is to receive regulatory approvals and successfully bring their innovative therapies to market, improving the lives of patients worldwide.